Approach to diagnosis and management of abnormal uterine bleeding

Case 1

Ms G. is a 26-year-old new patient in your practice who presents with a long-standing history of regular, heavy periods. She feels otherwise well, but the extent of her bleeding is worrying her. Review of systems is unremarkable, and results of physical examination, including pelvic examination, are normal.

Case 2

Mrs H., a 43-year-old woman with 3 children, comes to see you regarding her heavy periods. Over the years they have become heavier. She states that she “floods” the first few days and often has to stay home from work. She is chronically tired. On examination, she is pale, and her uterus is about the size it would be at 14 weeks’ gestation.

Case 3

Mrs S., a 61-year-old woman, has come to see you regarding several episodes of spotting. She has been postmenopausal for the past 12 years and has never taken hormone replacement therapy. She feels otherwise well. Her medications include 81 mg of acetylsalicylic acid, 5 mg of amlodipine, 10 mg of atorvastatin, and 37.5 mg of venlafaxine twice daily. Her physical examination is unremarkable.

Sources of information

MEDLINE was searched from 1996 to November 2004, EMBASE from 1996 to January 2005, and the Cochrane Database of Systematic Reviews (CDSR) from the 4th quarter of 2004 to the 3rd quarter of 2005. The Guideline Advisory Committee (GAC) database, the Canadian Medical Association Infobase for guidelines, and Clinical Evidence were also searched. Search terms used were the MeSH words uterine hemorrhage and menorrhagia for MEDLINE; the EMTREE subject headings uterus bleeding, menorrhagia, hypermenorrhea, and metrorrhagia for EMBASE; and menorrhagia as well as uterus or uterine or menstrual combined with bleeding or hemorrhage and abnormal or dysfunctional for the CDSR. Searches were limited to review articles involving human, female subjects. The quality of evidence ranged from level I to III.

Evaluation of AUB in premenopausal and perimenopausal women

The cause of AUB in premenopausal women is found in 50% to 60% of cases.1 The remaining cases, where no organic cause is found, are classified as dysfunctional uterine bleeding.2

History focuses on identifying the type of AUB—ovulatory, anovulatory, or anatomic—in order to guide treatment (Table 1). Ovulatory bleeding is more common, usually cyclic, and can be associated with midcycle pain, premenstrual symptoms, and dysmenorrhea.4 Anovulatory bleeding occurs more frequently at the extremes of reproductive age and in obese women. It is usually irregular and often heavy.5 Anovulatory bleeding poses a higher risk of endometrial hyperplasia.2 Polycystic ovarian syndrome is a common cause of anovulatory bleeding and is not discussed here. Fibroids or polyps are the most common cause of anatomic AUB2; 20% to 40% of women have fibroids.6 These women might present with abnormal bleeding, anemia, pain, and occasionally infertility. Some medications can also cause AUB (Table 27).

Physical examination includes looking for evidence of systemic disease. Pelvic and bimanual examinations are done to detect disease in the genital tract. Cervical cytology analysis should be current and normal, and cervical and vaginal swabs should be assessed to rule out infection.

Investigations

Investigations can include pregnancy testing if indicated and a complete blood count with ferritin. Other investigations might be done on the basis of clinical suspicion (Table 3). Coagulopathy should be ruled out when menorrhagia occurs at the start of menarche and there is no obvious pelvic disease. Von Willebrand disease is the most common coagulation disorder causing menorrhagia.8

Further investigations include ultrasonography to look for ovarian or uterine disease and endometrial biopsy. Transvaginal ultrasound is 80% sensitive and 69% specific for fibroids and polyps and is superior to transabdominal ultrasound.2 If possible, transvaginal ultrasound should be performed on days 4 to 6 of the menstrual cycle.9 In premenopausal women, there is no known correlation between endometrial thickness seen on ultrasound scan and endometrial disease.2

Endometrial biopsy is a simple office procedure that can be done by family physicians. The annual incidence of endometrial cancer is 19.5 per 100 000 women.10 Table 42 lists risk factors for endometrial cancer.2 One in 4 cases of endometrial carcinoma occurs before menopause, so biopsy should be considered for high-risk premenopausal patients10 (level II evidence, grade B recommendation), even in the presence of fibroids. Endometrial biopsy produces an adequate sample more than 85% of the time and detects 87% to 96% of endometrial carcinoma.2

Treatment for premenopausal and perimenopausal women

A patient’s degree of menorrhagia, associated pain, desire for pregnancy, concurrent medical conditions, and treatment side effects, and her physician’s comfort level should be taken into account when deciding on management2 (Table 514,15). Menorrhagia associated with ovulatory cycles can be treated with or without hormones. The anti-inflammatory medications mefenamic acid and naproxen have been studied most extensively and are equally effective at reducing menorrhagia.16 If started on day 1 of the menstrual cycle and continued for 5 days or until menses stop, these drugs can reduce bleeding by 22% to 46%12 (level I evidence). Antifibrinolytics are effective and underused. In the past, concern about increased risk of thrombosis limited use of these medications, but a recent Cochrane review showed no higher rate of thrombosis when compared with placebo or other therapies.17 For example, tranexamic acid has been shown to reduce menstrual blood loss by 34% to 59% over 2 to 3 cycles.18

Anovulatory menorrhagia might require endometrial protection with a combined oral contraceptive pill (COCP), the levonorgestrel intra-uterine system (LNG-IUS), or cyclic oral progestins. The LNG-IUS is a relatively new treatment that remains effective for 5 years. It has been found to reduce menstrual blood loss by 74% to 97%,18 and many women will be amenorrheic by 12 months.15 It is licensed in Canada for contraception only; using it for menorrhagia is an “off label” indication.

Asymptomatic fibroids do not require treatment.6 Menorrhagia caused by fibroids can be treated with tranexamic acid, low-dose COCPs, androgens, or GnRH agonists.6 There is no evidence for using nonsteroidal anti-inflammatory drugs, hormone replacement therapy, or oral progestins.6 Women who have acute heavy bleeding and are hemodynamically stable can be treated with low-dose progestin-dominant oral contraceptives at a dose of 2 to 4 pills a day for 7 days and then 1 pill a day for 2 weeks.15

Most family physicians refer patients for specialist care for AUB when treatment with androgens or gonadotropin-reducing hormone (GnRH) agonists is sought, but it is important to be aware of these options to discuss with patients. Androgens can reduce menstrual blood loss by up to 80%,12 but should be limited to 6 months due to androgenic side effects. The GnRH agonists also decrease menstrual blood loss, but the decrease in bone mineral density limits their use to 6 months.

Evaluation and treatment of AUB in postmenopausal women

Postmenopausal women presenting with vaginal bleeding must be evaluated. The most common cause of postmenopausal bleeding is vaginal atrophy (59%).9 It is important, however, to rule out endometrial carcinoma (10%) and cervical carcinoma (2%)10 (Table 619). Initial investigation of the endometrium is controversial. Endometrial biopsy, transvaginal ultrasound, or both can be done. What is done could depend on patient preference, physician comfort, and the availability of ultrasound scanning. The exact thickness of a normal endometrial lining in postmenopausal women as measured by ultrasound is also controversial. Several large studies have used 4 mm as the cutoff for further investigations (sensitivity 96% to 98%, specificity 36% to 68%).10 Figure 110,14 outlines management based on the results of endometrial biopsy.

• Download figure
• Open in new tab

Figure 1

Management of patients based on results of endometrial biopsy

Medical therapy for atrophic vaginitis

Atrophic vaginitis can be treated with topical estrogen cream (Premarin®), the newer tablets (Vagifem®), or a vaginal ring (Estring®); lubricants (Astroglide®, Lubrin®, or K-Y®); or moisturizers (Replens®) (level I evidence, grade B recommendation).20

Surgical options for menorrhagia

Dilation and curettage is no longer considered a treatment for menorrhagia because there is no long-term benefit (level II evidence). In fact, menstrual blood losses return to previous or higher levels by the second menstrual period following the procedure.15 Endometrial ablation is achieved by a variety of mechanisms, such as laser, electrical, thermal, or radiofrequency energy. It is done as an outpatient procedure under general anesthetic. About 85% of women have fewer symptoms, 10% require repeat ablation, and about 10% proceed to hysterectomy.1,11 Women older than 40 have been found to have better outcomes than those younger than 40.18 The procedure is not recommended for women wanting to preserve fertility. Hysterectomy is a permanent cure for menorrhagia, but the risks of major surgery must be weighed against risks of alternative management. In properly selected patients, hysterectomy might be the best choice.4 Hysterectomy is the recommended treatment for endometrial carcinoma. Uterine artery embolization and myomectomy are additional options for treating fibroids. Uterine artery embolization is a relatively new procedure. It resolves menorrhagia and pressure symptoms in 80% to 90% of cases,21 but there are risks associated with the procedure, and as of yet, no long-term data on its effectiveness.21 Myomectomy removes fibroids and conserves the uterus, but is appropriate only for certain types of fibroids. Although 80% of women see their symptoms improve,15 myomectomy might affect their ability to have vaginal deliveries.6 Postoperative recovery time is similar to that of hysterectomy.

Case 1 resolution

Ms G.’s situation represents either normal menstruation or ovulatory menorrhagia. Complete blood count and ferritin could be done, and transvaginal ultrasound to assess for fibroids could be considered. She could try nonsteroidal anti-inflammatory drugs during menstruation, or if she wants birth control, COCPs.

Case 2 resolution

An ultrasound scan of Mrs H. revealed 2 large fibroids. Due to her age, she underwent an endometrial biopsy9; results were negative. Her hemoglobin was 106 g/L and ferritin 7 mmol/L. She was started on iron replacement, as well as tranexamic acid. If these did not work, or the side effects were intolerable, she could be offered LNG-IUS, androgens, GnRH agonists, or surgery.

Case 3 resolution

Mrs S. had an endometrial biopsy; results were negative. She did not want estrogen cream and opted for a trial of lubricant applied daily. She continued to have spotting a few months later, and a transvaginal ultrasound was ordered. Results of this, as well as of a repeat endometrial biopsy were normal so she was referred to a gynecologist for further evaluation. If results of further investigations are negative, a review of her medications and a trial of discontinuation might be warranted.

LEVELS OF EVIDENCE

Level I: Evidence from at least one properly conducted randomized controlled trial

Level II-1: Evidence from well designed controlled trials without randomization

Level II-2: Evidence from well designed cohort or case-control analytic studies, preferably from more than 1 centre or research group

Level II-3: Evidence from comparisons between times or places with or without the intervention

Level III: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees

GRADES FOR RECOMMENDATIONS FOR SPECIFIC CLINICAL ACTIONS

Grade A: Good evidence to recommend the clinical action

Grade B: Fair evidence to recommend the clinical action

Grade C: Existing evidence conflicts and does not allow making a recommendation for or against taking the clinical action; however, other factors might influence decision making

Grade D: Fair evidence to recommend against the clinical action

Grade E: Good evidence to recommend against the clinical action

Grade I: Insufficient evidence to make a recommendation; however, other factors might influence decision making